

Product portfolio

March 2011

Our marketed vaccines currently combat 12 major infectious diseases. In 2010 we distributed more than 105 million vaccine doses in over 100 countries throughout the world. Our product portfolio consists of three distinct focus areas:

- Paediatric
- Travel & Endemic
- Respiratory

Paediatric:



Quinvaxem[®] is a fully liquid pentavalent (five-in-one) vaccine protects infants against five deadly childhood infections: diphtheria (D), tetanus (T), pertussis (P, whooping cough), hepatitis B (HepB), and Haemophilus influenzae type b (Hib). Since the launch of Quinvaxem[®] in 2006, over 180 million doses of this life-saving vaccine have been delivered to 50 GAVI countries. Most were low-income countries supplied through UNICEF and the Pan American Health Organization (PAHO). With this innovation, Crucell has become a major partner in protecting children in developing countries.



Hepavax-Gene[®] is a prophylactic recombinant vaccine against hepatitis B virus infection, providing long-term protection. With a track record of more than 500 million doses administered worldwide, it is also one of the established WHO pre-qualified vaccines.



MoRu-Viraten[®] is a safe, well-tolerated and effective vaccine for protection against measles and rubella in children, adolescents and adults. MoRu-Viraten[®] is free of egg proteins and antibiotics, posing no risk to children with allergies to these substances. The vaccine has been marketed since 1986 and is on the WHO list of vaccines for purchase by UN agencies.



Epaxal[®] Junior is a low dosage vaccine for the paediatric market with superior tolerability. It induces protective antibody levels within 10 days of primary vaccination and provides seroprotection for at least 30 years following the second (booster) dose. It can be fitted into the regular immunization schedule for babies.

Cruce

Travel & Endemic:



Epaxal[®] is the only aluminum-free hepatitis A vaccine on the market. The absence of aluminum reduces the pain when injected. Epaxal[®] induces protective antibody levels within 10 days of primary vaccination and provides

seroprotection for at least 30 years following the second (booster) dose. Its excellent efficacy and safety have been documented in many clinical trials and it is licensed in more than 40 countries worldwide.



Vivotif[®] is a live attenuated oral vaccine for the prevention of typhoid fever. It is the only oral vaccine indicated for use against *Salmonella typhi*, the most prevalent of the enteric fever-causing bacteria. Protective efficacy has been proven in several large-scale field trials

and it has an excellent track record for safety, having been on the market for more than 20 years. It is currently licensed in over 30 countries, including the USA. Results suggest that Vivotif[®] may be unique in also protecting against *S. paratyphi*, another common cause of enteric fever.



Dukoral[®] oral inactivated cholera vaccine provides safe, effective and convenient protection against cholera for people living in at-risk areas as well as visitors to these regions. Dukoral[®] was first licensed in 1992 and is now registered in 65 countries for the prevention of cholera,

with additional indications (ETEC, travelers' diarrhea) in some of these countries. It is an oral inactivated vaccine approved for use in adults and children from two years of age. Dukoral[®] drinkable vaccine is easy to use and offers 84 – 86% protection against cholera, as demonstrated in field clinical trials on various continents.

Respiratory:



Inflexal[®] V is a virosomal adjuvanted vaccine against influenza, based upon the virosome technology developed and patented by Cruce. It is the only adjuvanted flu vaccine licensed for all age groups (from six months). The vaccine's antigen composition follows yearly WHO

recommendations. Since its launch in 1997, Inflexal[®] V has been licensed in 38 countries with over 60 Million doses distributed. Extensive experience in the market has confirmed its efficacy and favorable safety profile.

We also distribute a variety of other products, such as Gardasil[®] (Merck) and Prolastin[®] (Talecris).

For more information about Cruce or our marketed products, please visit our website www.cruce.com.